Hologic, Inc.
HOLX
Get informed when a big investor buys or sells
+ FollowEarnings Call Q2 2023
May 1, 2023 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
70.6% upsideUndervalued by 70.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $16.97 Billion |
|---|---|
| Enterprise Value | $15.02 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.5 |
| Beta | 0.7 |
| Outstanding Shares | 224,405,000 |
Return
| Return on Equity | 10.37% |
|---|---|
| Return on Assets | 5.92% |
| Return on Invested Capital | 8.80% |
Valuation & Multiples
| P/E Ratio | 31.36 |
|---|---|
| PEG | -287.83 |
| Price to Sales | 5.85 |
| Price to Book Ratio | 3.3 |
| Enterprise Value to Revenue | 4.84 |
| Enterprise Value to EBIT | 20.74 |
| Enterprise Value to Net Income | 27 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 5.0823▼ 43.17% |
|---|---|
| Total Calls | 390,100▲ 127.60% |
| Total Puts | 1,982,600▲ 109.78% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 94.77%▼ 0.98% |
|---|---|
| Total Invested | $16.07B▲ 0.35% |
| Investors Holding | 719▼ 47.00% |
ESG Score
No data
About Hologic, Inc.
6,478 employees
CEO: Stephen MacMillan Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment.
Relevant Senate Committees
This committee controls taxation and entitlement spending. Its decisions on corporate tax policy directly affect Hologic's profitability, and its influence over Medicare pricing is critical for reimbursement of medical procedures and devices.
This committee directly allocates federal spending across all government agencies, including healthcare programs (e.g., NIH, VA, Medicare/Medicaid funding), significantly impacting Hologic's customer base and R&D opportunities.
This committee directly regulates the FDA, which is the primary regulatory body for Hologic's medical devices and diagnostics, and influences NIH funding for related research.